Santhera Finds ‘Elegant Solution’ For Its Finances With Catalyst DMD Drug Deal

US Rights To Vamorolone Licensed For $90m Upfront

The Swiss rare diseases firm Santhera has signed a licensing deal for its Duchenne muscular dystrophy drug vamorolone, which could be launched in both the US and the EU by the end of the year, paying off short-term debt and cleaning up the balance sheet.

Eklund_Dario_1200
Dario Eklund • Source: Santhera

With regulatory decisions imminent on both sides of the Atlantic for vamorolone, Santhera Pharmaceuticals has secured a North America partner for the closely watched Duchenne muscular dystrophy (DMD) therapy while banking a healthy upfront payment.

The Swiss group has signed a license and collaboration agreement for vamorolone with Catalyst Pharmaceuticals, Inc. covering the US,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip